High-sensitivity monitoring of ctDNA by patient-specific sequencing panels and integration of variant reads 2 One Sentence Summary: Integrating tumor-derived sequences across large panels of patientspecific mutations offers enhanced sensitivity for ctDNA detection and monitoring from both high-depth and low-depth plasma sequencing data.
Introduction
Circulating tumor DNA (ctDNA) can be robustly detected in plasma when multiple copies of 55 mutant DNA are present; however, when ctDNA levels are low, analysis of individual mutant loci might produce a negative result due to sampling noise even when using an assay with perfect analytical sensitivity. Such "missed" samples can have low fractional concentrations of ctDNA (relatively few mutant molecules in a high background), or low absolute numbers of mutant molecules due to limited sample input (Fig. 1A) . This effect of limited sampling reduces the 60 sensitivity of ctDNA monitoring for patients with early-stage cancers, or following treatment for Wan & Heider et al., September 2019 High-sensitivity monitoring of ctDNA by patient-specific sequencing panels and integration of variant reads 4 identify artefactual signal at a given locus by comparison of the given allelic fraction against the allele fractions at other patient-specific loci. Furthermore, greater weight may be assigned to fragments more likely to arise from tumor cells based on their biological characteristics such as fragment size (15) , thereby enhancing the signal to noise ratio. 95 Here, we present a workflow for enhanced patient-specific monitoring that is optimized for sensitive detection of ctDNA to parts per million, using patient-specific sequencing data and custom hybrid-capture panels (Fig. 2C , flowchart in Fig. S1 ). This approach leverages custom error-suppression and signal enrichment methods to enable sensitive monitoring and identification of residual disease. We further demonstrate the ability to apply INVAR to plasma 100 whole-exome sequencing (WES) and shallow whole genome sequencing (sWGS), demonstrating improved sensitivity for detection and quantification of ctDNA.
Tumor genotyping
First, tumor genotyping was performed to identify multiple patient-specific mutations per 105 patient: exome sequencing data was generated from tumor and buffy coat samples from 47 patients with Stage II-IV melanoma (Methods), identifying a median of 625 mutations per patient (IQR 411-1076, Fig. S2 and Table S1 ). These mutation lists were used to generate custom capture sequencing panels, which were used to sequence longitudinal plasma samples (n=144) (2,301x mean raw depth). In addition, WES (238x mean raw depth, n=20) and sWGS 110 (0.6x mean raw depth, n=33), was performed on samples from the same patients and used as input for INVAR analysis (Tables S2 and S3 ).
Characterizing background error rates
We started by characterizing background error rates in hybrid-capture sequencing data. 115 Approximation of error rates may potentially be achieved through grouping mutations of similar class. We demonstrate that error rates vary between mutation class by over an order of magnitude using raw sequencing data without using molecular barcodes (Fig. 3A) , consistent with Newman et al. (10) . To increase the resolution of background error rates further, we grouped mutations by both mutation class and trinucleotide context, demonstrating over two Wan & Heider et al., September 2019 High-sensitivity monitoring of ctDNA by patient-specific sequencing panels and integration of variant reads 5 orders of magnitude difference in background error rate between the least and most noisy trinucleotide context (Fig. 3B ).
Using a patient-specific sequencing approach, a large number of private mutation loci were targeted. Each locus has its own error rate, though accurate benchmarking of the background noise rates of individual loci to levels below 10 -6 would require the cfDNA 125 molecules from a total of 100mL of plasma in order to sample one mutant read. This assumes a cfDNA concentration of 10ng/mL from plasma, yielding 3 million analyzable molecules. Thus, we sought to develop a background error model for patient-specific sequencing data that could estimate the background error rate of a locus accurately using limited control samples. In this study, 99.8% of the mutations identified by tumor sequencing were private i.e. unique to each 130 individual. We assessed if patients may be used to control for other patients' mutation lists, thereby enabling us to group patient-specific mutation lists of multiple patients together and reduce the number of additional control samples to be run on each panel. In this study, a mean of 5.5 patients were included on each custom hybrid-capture sequencing panel design. There was no significant difference in background error rate whether using healthy individuals or other 135 patients serving as controls ('patient-control' samples, which may control for other patients at private loci) ( Fig. 3C ). Thus, INVAR utilizes sequencing data from one patient to control for others with both custom and untargeted approaches such as exome or WGS ( Fig. 3D ). 140 As part of the INVAR pipeline, we sought to develop methods to minimize artefacts in patient-specific sequencing data. Read collapsing was performed using unique molecular barcodes which reduced error rates across all mutation classes ( Fig. S3A ), similar to previous studies (16). Increasing the minimum number of duplicates required per read family reduced error rates further, but at the expense of a greater fraction of the sequencing data being discarded 145 ( Fig. S3B ). To balance data loss against background error rate, a minimum family size threshold of 2 was used.
Error-suppression in patient-specific sequencing data
INVAR requires any mutation signal to be represented in both the forward (F) and reverse (R) read of the read pair. This serves to both reduce sequencing error and produces a small size-selection effect for short fragments since only short fragments would be read completely in both F and R with paired-end 150bp sequencing. This step retained 92.4% of mutant reads and 84.0% of wild-type reads in a training dataset ( Fig. S3C ).
When targeting a large number of patient-specific loci, it becomes increasingly likely that technically noisy sites, or single-nucleotide polymorphism (SNP) loci are included in the list.
Newman et al. have previously utilized position specific polishing to address this issue (10) . In 155 this study we blacklisted loci that showed either error-suppressed mutant signal in >10% of the patient-control samples, or a mean background error rate of >1% mutant allele fraction. This approach excluded 0.5% of the patient-specific loci (Fig. S3D ). Requiring mutant signal in both reads and applying a locus noise filter reduced noise modestly when applied individually; however, when combined they showed a synergistic effect, reducing background error rates to 160 below 1x10 -6 in some mutation classes (Figs. 4A, S3E). The individual effects of these filters on individual trinucleotide contexts are shown in Fig. S3F .
When targeting a large number of patient-specific sites, it becomes possible to assess the distribution of allele fractions observed. In the residual disease setting, we expect to have a high degree of sampling error. Therefore, signal should appear stochastically as individual mutant 165 molecules distributed across patient-specific loci, with many of the loci having zero mutant reads. In order to optimize INVAR for detection of the lowest possible levels of ctDNA, we developed a method called patient-specific outlier suppression to exclude signal at a locus that is not consistent with the remaining loci (Figs. S3G and 4B). This tests each locus against the distribution of signal at all other loci with a correction for multiple testing, excluding loci that are 170 significantly outlying. Mutant signal was reduced 3-fold in control samples, while retaining 96.1% of mutant signal in patient samples ( Fig. 4C ).
Overall, combining the above steps results in an average 131-fold decrease in background error relative to raw sequencing data ( Fig. 4A ) and reduces the error rates of some trinucleotide contexts to below 10 -6 ( Fig. S3E ).
Patient-specific signal enrichment
To enhance detection further, INVAR is able to enrich for ctDNA signal through probability weighting based on the tumor allele fraction of each mutation locus and ctDNA Wan & Heider et al., September 2019 High-sensitivity monitoring of ctDNA by patient-specific sequencing panels and integration of variant reads 7 fragment sizes. Tumor mutations with a higher tumor allelic fraction are more likely to be 180 observed in the plasma (8, 17) , therefore, greater weight was allocated to mutant signals in plasma from loci with high tumor mutant allele fraction. Using a dilution series, we confirm the relationship between the tumor allele fraction of a locus and rate of detection of ctDNA of that locus in plasma ( Fig. S4A ). We confirm in clinical samples that patient-specific mutation loci observed in plasma had a significantly higher tumor allele fraction compared to those not 185 observed in plasma (P = 2x10 -16 ; Wilcoxon test, Fig. 4D ).
Analysis of 144 samples showed a nucleosomal pattern of cfDNA fragmentation, with mutant fragments shorter than wild-type fragments at the mono-nucleosome and di-nucleosome peak ( Fig. S4B ). We also observed that stage IV melanoma patients had a significantly higher median mutant fragment size compared to the stage II-III melanoma patients (163bp vs. 154bp, P 190 = 2x10 -16 , Wilcoxon test, Fig. S4C ). Previous research has shown enrichment for ctDNA when shorter fragments are selected using either in vitro or in silico size selection (15, 18, 19) . However, at low levels of signal, such methods can cause loss of rare mutant alleles (20) . Thus, in this study we weighted each signal based on its fragment size in order to boost ctDNA signal, while retaining all the data (Fig. 4E ). Based on smoothed size profiles of mutant and wild-type 195 fragments observed ( Fig. S4D ), patient data were used to size-weight other patients' data using a leave-one-out approach (Supplementary Methods).
Following signal weighting, INVAR aggregates signal across all patient-specific mutations (Methods). In order to determine whether or not ctDNA is detected in a sample, data from non-matched mutations in other patients were used as negative controls to set the detection 200 threshold ( Fig. S5 ). An Integrated Mutant Allele Fraction (IMAF) is determined by taking a background-subtracted, depth-weighted mean allele fraction across the patient-specific loci in each sample (Supplementary Methods).
Analytical sensitivity and specificity of INVAR
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To benchmark the sensitivity of INVAR, we performed custom capture sequencing of a dilution series of plasma from one melanoma patient (stage IV disease), for whom we identified 5,073 mutations through exome sequencing. Plasma DNA from this patient was serially diluted into control volunteers' plasma DNA to an expected IMAF of 3.6 x 10 -7 . Without use of unique Wan & Heider et al., September 2019 High-sensitivity monitoring of ctDNA by patient-specific sequencing panels and integration of variant reads 8 molecular barcodes, INVAR detected ctDNA down to an expected allele fraction of 3.6 x 10 -5 , 210 which was quantified to an average IMAF of 4.7 x 10 -5 from two replicates ( Fig. 5A ). Following the use of molecular barcodes and custom error-suppression methods, the diluted ctDNA was detected to an expected IMAF of 3.6 x 10 -6 (3.6 parts per million) in two replicates, with IMAF values of 4.3 and 5.2 ppm. Overall, the correlation between IMAF and the expected mutant fraction was 0.98 (Pearson's r, p < 2.2 x 10 -16 , Fig. 5A ). At an expected allele fraction of 3.6 x 215 10 -7 , ctDNA was detected in 2 out of 3 replicates. To assess the impact on sensitivity of the number of mutations targeted we downsampled sequencing data in silico to include subsets of patient-specific mutation lists. This confirmed that targeting more mutations resulted in more IR and correspondingly higher ctDNA detection rates ( Fig. 5B , Supplementary Methods).
The false positive rate of INVAR was measured twice, once in patient-control samples 220 and separately in healthy control samples. First, analytical specificity was determined through analysis of samples from other patients (patient-control samples) at non-matched mutation loci, giving a median specificity of 98.0% ( Fig. S6 , Table S4 ). To confirm the specificity of INVAR in independent control samples, we ran custom capture sequencing (with the same oligo pools) on samples from healthy individuals and analyzed those by INVAR using each of the patient-225 specific mutation lists. The ROC curve for the stage IV melanoma cohort controlled against healthy individuals is shown in Fig. 5C . Across each of the analyses in this study, using control cfDNA from 26 healthy individuals, a median specificity value of 97.05% was obtained, consistent with the analytical specificity defined in non-matched control samples from other patients ( Fig. S6 ).
230
Quantification of ctDNA in patient samples
We applied INVAR to custom capture panel sequencing data from 130 plasma samples from 47 stage II-IV melanoma patients, generating up to 2.9 x 10 6 IR per sample (median 1.7 x 10 5 IR), thus analyzing orders of magnitude more cfDNA fragments compared to methods that 235 analyze individual or few loci ( Fig. 6A ). In this study, we demonstrated a dynamic range of 5 orders of magnitude and detection of trace levels of ctDNA in plasma samples (Figs. 6B, 6C); this detection was obtained from a median input material of 1638 copies of the genome (5.46 ng of DNA; Table S2 ). In a total of 13 of the 130 plasma samples analyzed with custom capture sequencing, ctDNA was detected with signal in fewer than 1% of the patient-specific loci ( Fig.   240 6D). The lowest fraction of cancer genomes detected was 1/714, equivalent to <5 femtograms of tumor DNA. Given the limited input, the low ctDNA levels detected would be below the 95% limit of detection for a 'perfect' single-locus assay in 48% of the cases (indicated with filled circles in Fig. 6C ). The input mass vs. IMAF of each sample is shown in Fig. S7A , highlighting the sensitivity benefit of a broad sequencing approach. Thus, targeting multiple mutations can 245 allow detection of low absolute amounts of tumor-derived DNA.
In Stage IV melanoma patient samples, ctDNA IMAF values showed a correlation of 0.8 with tumor size assessed by CT imaging (Pearson's r, P = 6.7 x 10 -10 , Fig. S7B , Table S5 Fig. S8A . We interrogated a median of 3.6 x 10 5 IR (IQR 0.64 x 10 5 to 4.03 x 10 5 ) and detected ctDNA to a minimum IMAF of 2.85 ppm, indicated >250,000 informative reads (detection limit below 10 ppm) and in 5 of 6 (83%) cases with >10 6 270 informative reads ( Fig. 6B ). Samples with no ctDNA detected and few informative reads may indicate limited resolution and would benefit from additional information (more informative reads, obtainable from deeper sequencing or more mutations). A similar approach was previously described in the relative haplotype dosage method by Lo et al. (22) . In our case, excluding 3 samples where ctDNA was undetected and had fewer than 20,000 informative reads (detection 275 resolution of 0.01% not reached), ctDNA was detected in 8 of 20 (40%) patients who later recurred and was associated with a strong trend for shorter disease-free interval (6.3 months vs. median not reached with 5 years' follow-up; Hazard ratio (HR) = 2.08; 95% CI 0.85-5.13, P = 0.11) and overall survival (2.6 years vs. median not reached, P = 0.08). In comparison, a previous analysis of ctDNA detection at 12 weeks after surgery in 161 patients with resected 280 BRAF or NRAS mutant melanoma detected ctDNA in 16.8% of patients who later relapsed (5) .
Sensitive ctDNA monitoring using WES and sWGS
Patient-specific capture panels allow highly sensitive detection of ctDNA, but require prior design of patient specific capture panels. Therefore, we assessed whether INVAR could be 285 applied to standardized workflows such as WES or WGS. This allows the panel design step to be omitted and requires only the patient-specific mutation list from tumor sequencing, which may be performed in parallel with plasma sequencing to save time ( Fig. 7A ).
To test the generalizability of INVAR, we selected samples with IMAF values quantified as being between 4.5 x 10 -5 and 0.16 using custom-capture sequencing and utilized commercially 290 available exome capture kits to sequence plasma DNA to a median raw depth of 238x. Despite the modest depth of sequencing, we obtained between 1,565 and 473,300 IR using WES ( Fig.   7B ). We detected ctDNA in all 20 samples tested down to IMAFs as low as 4.34 x 10 -5 ( Fig. 7C ), demonstrating that ctDNA can be sensitively detected by INVAR from WES data using patientspecific mutation lists. These IMAF values showed a correlation of 0.97 with custom capture
We hypothesized that ctDNA could be detected and quantified with INVAR from even 300 smaller amounts of input data. Therefore, we performed WGS on libraries from cfDNA of longitudinal plasma samples from a subset of six patients with Stage IV melanoma, to a mean depth of 0.6x (indicated in black in Fig. 7B ). For each of those patients we identified >500 patient-specific mutations using WES from each patient's tumor and buffy coat DNA, generating between 226 and 7,696 IR per sample (median 861, IQR 471-1,559; Fig. 7B ) with a "minimum 305 family size" requirement of 1 (i.e. duplicate removal). Despite not leveraging unique molecular barcodes, error rates per trinucleotide were still sufficiently low, with many trinucleotide contexts showing error rates below 1 x 10 -5 ( Fig. S9 ). Using INVAR on sWGS data, IMAF values as low as 1.1 x 10 -3 were quantified ( Fig. 7F ). Compared to custom capture data from the same samples we observed a correlation of 0.93 (Pearson's r, P = 9 x 10 -10 , Fig. 7D ). In samples 310 where ctDNA was not detected, it was possible to estimate the maximum likely IMAF of that sample from the known number of informative reads for each sample, which is indicated by the grey bars in Fig. 7F . Using less than 1x coverage, INVAR can boost the sensitivity utilizing patient-specific mutation lists by up to an order of magnitude compared to copy-number analyses (15, 23) . 315 These analyses suggest that with a sufficiently large number of tumor -specific mutations, INVAR may yield high sensitivity for ctDNA detection from untargeted sequencing data that can be limited in depth and thus input material obtainable, for example, from dried blood spots (24) . 320 The sensitivity of INVAR depends on the number of patient-specific mutations identified, and so its effectiveness may be limited in samples with fewer identified mutations, or in cancers with lower mutation rates. Fig. 8A shows the distribution of IR for all the samples in this study, highlighting those with limited sensitivity (<20,000 IR) and those with sensitivity to ppm.
Extrapolation to higher IR and sensitivity
Samples with limited sensitivity could be re-analyzed with larger amounts of DNA input/more 325 sequencing, or by designing larger capture panels by identifying additional patient specific mutations through broader-scale sequencing such as WGS of the tumor and buffy coat DNA from that patient. Analyses involving greater IR would render the current background error rates limiting and would therefore require greater error-suppression, such as duplex molecular Wan & Heider et al., September 2019 High-sensitivity monitoring of ctDNA by patient-specific sequencing panels and integration of variant reads 12 barcodes (25) . However, when increasing the sensitivity of ctDNA beyond the ppm range, 330 sequencing output may become the limiting factor.
We studied the ctDNA levels in the samples analyzed with custom capture in order to estimate the levels of sensitivity that would be required for different clinical applications. We used IMAF values from the clinical samples and plotted the detection rates while varying the numbers of IR and the levels of sensitivity (Fig. 8B ). In Stage IV melanoma patients at pre-335 treatment baseline time points, ctDNA was detected in 100% of cases using 10 5 IR, whereas up to two orders of magnitude greater sensitivity may be needed to detect ctDNA at high rates following treatment initiation ( Fig. S8B ). For the population we studied of Stage II-III melanoma patients who underwent surgery, we suggest that even analysis of 10 7 IR might not be sufficient to detect all patients who ultimately relapse. 340 
Discussion
In this study, we developed a method for sensitive patient-specific monitoring of ctDNA that leverages the properties of patient-specific sequencing data. This approach mitigates sampling error through aggregation of mutant signal, which is first weighted based on the 345 features of each read and mutation locus, and uses features of cfDNA aside from specific sequence alterations, such as fragment sizes and tumor allele fractions of each mutation. By aggregating signal across 10 2 -10 4 mutated loci it is possible to detect <0.01 copies of a cancer genome, even when this represents few parts per million of the cfDNA in plasma, 1-2 orders of magnitude lower than previous studies (6, 10) . 350 We show that INVAR can be applied not only to patient-specific capture panel data to quantify ctDNA to parts per million ( Fig. 6 ), but also to exome sequencing and sWGS data ( Fig.   7 ). Although these latter methods generated fewer informative reads, INVAR detected ctDNA to 50 ppm using WES, and to 0.1% mutant allele fraction using sWGS, over an order of magnitude more sensitive compared to previous methods based on copy-number analysis of sWGS (23, 26) . 355 This level of sensitivity can only be achieved by targeting a sufficiently large number of patientspecific mutations, as increasing input mass alone would not be feasible to this extent ( Fig. 2A) .
Therefore, we assessed whether INVAR would still retain sufficient sensitivity when applied to sWGS data from other cancer types with lower mutation rates than melanoma. We estimated the Wan & Heider et al., September 2019 High-sensitivity monitoring of ctDNA by patient-specific sequencing panels and integration of variant reads 13 potential sensitivity for INVAR using sWGS on other cancer types based on their known whole-360 genome mutation rates (27) (Fig. 8C ). Using 0.1x WGS coverage, INVAR may yield sensitivities of 10 -1 -10 -3 for these cancer types, with the potential for higher sensitivity with deeper sequencing.
In summary, patient-specific mutation lists provide an opportunity for highly sensitive monitoring from a range of sequencing data types using methods for signal aggregation, 365 weighting and error-suppression. As tumor sequencing becomes increasingly performed in personalized oncology, patient-specific mutation lists may be leveraged for individualized monitoring using INVAR-like tools. were centrifuged at 1,600 g for 10 minutes within an hour of the blood draw, and then an 390 additional centrifugation of 20,000 g for 10 minutes was carried out. All aliquots were stored at -
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80°C.
Tissue and plasma extraction and quantification. FFPE samples were sectioned into up to 8 µm sections, and one H&E stained slide was generated, which was outlined for tumor regions by 395 a histopathologist. Marked tumor regions were macrodissected, and DNA extraction was performed using the QIAamp DNA FFPE Tissue Kit using the standard protocol, except with incubation at 56°C overnight and 500 rpm agitation on a heat block. DNA was eluted twice using Wan & Heider et al., September 2019 High-sensitivity monitoring of ctDNA by patient-specific sequencing panels and integration of variant reads 15 20 µL ATE buffer each time with centrifugation at full speed. Following extraction, DNA repair was performed using the NEBNext® FFPE DNA Repair Mix as per the manufacturer's protocol. 400 Fresh frozen tissue biopsies were first homogenized prior to DNA extraction, which was performed as follows: up to 30 mg of each fresh frozen tissue biopsy sample was combined with 600 µL RLT buffer, then placed in a Precellys CD14 tube (Bertin Technologies) and homogenized at 6,500 rpm for two bursts of 20 seconds separated by 5 seconds. Subsequently, the Qiagen AllPrep extraction kit as per the manufacturer's protocol. 405 Genomic DNA was extracted from up to 1 mL whole blood or buffy coat using the In addition, for FFPE data in the melanoma cohort, the filter for C/A errors proposed by Costello et al. (31) was applied to suppress C/A artefacts. As a result, we generated patient-455 specific mutation lists for 47 patients with stage II-IV melanoma. A median of 625 (IQR 411 -1076) patient-specific mutations were identified per patient (Fig. S2, Table S1 ). These mutation lists were used both to design custom capture sequencing panels, and as input for the INVAR method. Fig. S2 and Table S1 .
Libraries were captured either in single or 3-plex (to a total of 1000 ng capture input) using the Agilent SureSelectXT protocol, with the addition of i5 and i7 blocking oligos (IDT) as recommended by the manufacturer for compatibility with ThruPLEX libraries (32) . Custom libraries were purified with AMPure XP beads at a 1:1.8 ratio, then were quantified and library fragment size was determined using a Bioanalyser (Agilent).
Exome capture sequencing of plasma. For exome sequencing of plasma, the Illumina TruSeq 490 Exome capture protocol was followed. Libraries generated using the Rubicon ThruPLEX protocol (as above) were pooled in 3-plex, with 250ng input for each library. Libraries underwent two rounds of hybridization and capture in accordance with the protocol, with the addition of i5 and i7 blocking oligos (IDT) as recommended by the manufacturer for compatibility with ThruPLEX libraries. Following target enrichment, products were amplified 495 with 8 rounds of PCR and purified using AMPure XP beads prior to QC.
Plasma sequencing data processing. Cutadapt v1.9.1 was used to remove known 5' and 3' adaptor sequences specified in a separate FASTA of adaptor sequences. Trimmed FASTQ files were aligned to the UCSC hg19 genome using BWA-mem v0.7.13 with a seed length of 19. 500 Error-suppression was carried out on ThruPLEX Tag-seq library BAM files using CONNOR (33). The consensus frequency threshold -f was set as 0.9 (90%), and the minimum family size threshold -s was varied between 2 and 5 for characterization of error rates. For custom capture and exome sequencing data, a minimum family size of 2 was used. For sWGS analysis, a minimum family size of 1 was used, i.e. not using molecular barcodes except for where 505 duplicates are present.
To leverage signal across multiple time points, error-suppressed BAM files could be combined using `samtools view -ubS -| samtools sort -` prior to further data processing. In the early-stage melanoma cohort (AVAST-M), where multiple samples were available for the same patient before 6 months post-surgery, sequencing data for each of the samples were merged. Imaging. CT imaging was acquired as part of the standard of care from each patient of the stage IV melanoma cohort and was examined retrospectively. Slice thickness was 5 mm in all cases.
All lesions with a diameter greater than 5 mm were outlined slice by slice on CT images by an experienced operator, under the guidance of a radiologist, using custom software written in 530 MATLAB (Mathworks, Natick, MA). The outlines were subsequently imported into the LIFEx software (34) in NifTI format for processing. Tumor volume was then reported by LIFEx as an output parameter from its texture-based processing module (Table S5 ).
Data and materials availability. Raw sequencing data will be made available at the European 535 Genome-phenome archive, accession number EGAS00001002959.
Supplementary Materials
Materials and Methods Table S2 Sample library preparation input, QC, and INVAR likelihood ratios -test samples. Table S3 . Sample library preparation input, QC, and INVAR likelihood ratios -control samples. typically results in ~10,000 IR, leading to frequently encountered detection limits of 0.01%-0.1% (9, 13) . In this study we focused on analysis of larger numbers (100s-1000s) of mutations, including deep sequencing by patient-specific hybrid-capture panels or limited input. mL, milliliter; µL, microliter. (B) To generate deep sequencing data across large patient-specific mutations lists at high depth, patient-specific mutation lists generated by tumor genotyping were used to design hybrid-capture panels, that were applied to DNA extracted from plasma samples.
In later sections, the tumor genotyping data is used to analyze sequencing data from standard , and control data is obtained by analyzing the same loci in additional patients from the same cohort for whom the loci were not found to be 810 mutated in the tumor or buffy coat analysis. Such data can be generated by applying a standardized sequencing approach, such as WES/sWGS, to all samples (Fig. 7) or by combining multiple patient-specific mutation lists into a custom capture panel that is sequenced across multiple patients (Fig. 6) . Data from other patients in those loci ('non-matched mutations') are used to determine background mutation rates and a ctDNA detection cut-off. (E) Log2 enrichment ratios for mutant fragments from three different cohorts of patients. Size ranges enriched for ctDNA are assigned more weight by the INVAR pipeline. its fractional concentration (IMAF) was higher than 2/IR (falling above the dashed line, which is 850 plotted at 1/IR). In some samples, >10 6 IR were obtained, and ctDNA was detected down to fractions of few ppm (orange shaded region). In some samples, few IR were obtained resulting in limited sensitivity. In our study we used a threshold of 20,000 IR (left-most dotted line), such that samples with undetected ctDNA with fewer than 20,000 IR were called "unclassified" and excluded from the analysis (total of 6 of 144 samples; dark blue shaded region). Samples outside 855 this region had detected ctDNA, or had estimated ctDNA levels below 0.01% (undetected with >20,000 IR; confidence ranges for this value vary for each sample depending on IR). An alternative threshold could be used, for example 66,666 IR, resulting in detection level of 0.003% or 30 ppm (indicated by the second dotted line and the light blue shaded region), increasing the overall detection rates in the cohorts. (C) ctDNA fractional levels (IMAF) 860 detected in the samples in this study, shown in ascending order for the two cohorts. Filled circles indicate samples where the number of haploid genomes analyzed would fall below the 95% limit of detection for a perfect single-locus assay given the measured IMAF (Supplementary Methods). Empty circles indicate unclassified samples, i.e. samples for whom ctDNA was not detected (ND) with IR < 20,000. (D) The number of copies of the cancer genome detected for 865 each of the samples in the same order as above in part (C), calculated as the number of mutant fragments divided by the number of loci queried (Table S2 ). (E) ctDNA IMAF and tumor volume are plotted over time for one patient with metastatic melanoma over the course of several treatment lines (indicated by shaded boxes). ctDNA was detected to 2.5 ppm during treatment with anti-BRAF targeted therapy, when disease volume was approximately 1.3 cm 3 . High-sensitivity monitoring of ctDNA by patient-specific sequencing panels and integration of variant reads 37 stage II-III melanoma post-surgery (red), a linear relationship was observed between IR and detection rate, and the predicted rates of detection of ctDNA was extrapolated. ND, not detected.
(C) Predicted sensitivities for sWGS plasma analysis of patients with different cancer types, 915 using an average of 0.1x or 10x coverage (equivalent to 0.1 and 10 hGA) and the known mutation rates per Mbp of the genome for different cancer types (27) . The limit of detection for ctDNA based on copy number alterations is shown at 3% (23).
